Jim Cramer on Eli Lilly's Covid-19 phase 2 trial results for antibody drug

Eli Lilly announced on Wednesday it had found proof of concept data from an interim analysis of the BLAZE-1 clinical trial that showed a reduced rate of hospitalization for coronavirus patients treated with its neutralizing antibody drug. CNBC's "Squawk on the Street" crew discusses the status of getting a coronavirus candidate approved and what it could mean for the markets and the economy. Subscribe to CNBC PRO for access to investor and analyst insights: https://cnb.cx/2Vtntx6

» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic

Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC

For info on the best credit cards go to CNBC Select:
https://www.cnbc.com/select/best-credit-cards/

#CNBC
#CNBCTV

Видео Jim Cramer on Eli Lilly's Covid-19 phase 2 trial results for antibody drug канала CNBC Television